Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(2): 271-276
Qin Xiaoyan, Liu Yanyao, Kang Quan. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018
Citation: Qin Xiaoyan, Liu Yanyao, Kang Quan. Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(2): 271-276. doi: 10.3969/j.issn.1674-7445.2022.02.018
shu

Prevention and therapeutic strategies and targeted immunotherapy for hepatocellular carcinoma recurrence and metastasis after liver transplantation

doi: 10.3969/j.issn.1674-7445.2022.02.018

  • Department of General Surgery and Trauma Surgery of Yuzhong District, Children's Hospital of Chongqing Medical University, Key Laboratory of Child Development and Disorders of Ministry of Education, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

More Information
  • Corresponding author: Kang Quan, Email: 564799351@qq.com
  • Received Date: 2021-11-03
    Available Online: 2022-03-18
  • Publish Date: 2022-03-15
    Abstract
  • With the development and maturity of liver transplant techniques, liver transplantation has become one of the vital treatment options for hepatocellular carcinoma (HCC). Postoperative recurrence and metastasis of HCC after liver transplantation is one of critical factors that affect the long-term survival of recipients. Exploring the prevention and therapeutic strategies for HCC recurrence and metastasis after liver transplantation plays a pivotal role in improving the clinical efficacy of liver transplantation for HCC recipients. Intimate monitoring, active prevention, early diagnosis, comprehensive surgical treatment and local treatment, especially targeted immunotherapy, and individualized prevention and therapeutic strategies are of significance for the prevention and treatment of HCC recurrence and metastasis after liver transplantation. In this article, the monitoring, diagnosis, prevention and treatment of tumor recurrence and metastasis after liver transplantation for HCC were reviewed, aiming to provide reference for the prevention and treatment of tumor recurrence and metastasis after liver transplantation, enhancing clinical efficacy of liver transplantation and prolonging the survival of recipients.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.

    LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
    [3]
    YOH T, SEO S, TAURA K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival[J]. Ann Surg, 2021, 273(4): 792-799. DOI: 10.1097/SLA.0000000000003358.
    [4]
    SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217. DOI: 10.1038/nrgastro.2016.193.
    [5]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [6]
    RUDNICK SR, RUSSO MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(3): 265-275. DOI: 10.1080/17474124.2018.1417035.
    [7]
    刘召波, 栗光明. 肝移植术后肝癌复发防治进展[J]. 临床肝胆病杂志, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.

    LIU ZB, LI GM. Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Hepatol, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.
    [8]
    刘少儒, 许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.

    LIU SR, XU LB. Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer[J]. Organ Transplant, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.
    [9]
    KIM JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?[J]. Clin Mol Hepatol, 2021, 27(4): 562-563. DOI: 10.3350/cmh.2021.0276.
    [10]
    SATAPATHY SK, DAS K, KOCAK M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246. DOI: 10.1111/ctr.13246.
    [11]
    GIAKOUSTIDIS AE, GIAKOUSTIDIS DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma[J]. Immunotherapy, 2017, 9(2): 197-206. DOI: 10.2217/imt-2016-0110.
    [12]
    中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
    [13]
    FOERSTER F, HOPPE-LOTICHIUS M, VOLLMAR J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849. DOI: 10.1177/2050640619840221.
    [14]
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [15]
    郑树森, 程启阳, 耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.

    ZHENG SS, CHENG QY, GENG L, et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma: recent research progress[J]. Chin J Gen Surg, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.
    [16]
    LI M, WANG Z, CAO J, et al. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections[J]. Eur J Surg Oncol, 2019, 45(9): 1684-1690. DOI: 10.1016/j.ejso.2019.04.008.
    [17]
    FERNANDEZ-SEVILLA E, ALLARD MA, SELTEN J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447. DOI: 10.1002/lt.24742.
    [18]
    ROAYAIE S, BASSI D, TARCHI P, et al. Second hepatic resection for recurrent hepatocellular cancer: a Western experience[J]. J Hepatol, 2011, 55(2): 346-350. DOI: 10.1016/j.jhep.2010.11.026.
    [19]
    YAMASHITA Y, SHIRABE K, TSUIJITA E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Surgery, 2013, 154(5): 1038-1045. DOI: 10.1016/j.surg.2013.04.046.
    [20]
    BALE R, SCHULLIAN P, EBERLE G, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers[J]. Hepatology, 2019, 70(3): 840-850. DOI: 10.1002/hep.30406.
    [21]
    OLIGANE HC, XING M, KIM HS. Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation[J]. Radiology, 2017, 282(3): 869-879. DOI: 10.1148/radiol.2016160288.
    [22]
    SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6.
    [23]
    INVERNIZZI F, IAVARONE M, CZAUDERNA C, et al. Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study[J]. Digest Liver Dis, 2019, 51(Suppl 1): e12. DOI: 10.1016/j.dld.2018.11.058.
    [24]
    KWONG A, KIM WR, LAKE JR, et al. OPTN/SRTR 2018 annual data report: liver[J]. Am J Transplant, 2020, 20(Suppl s1): 193-299. DOI: 10.1111/ajt.15674.
    [25]
    VIVARELLI M, CUCCHETTI A, PISCAGLIA F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression[J]. Liver Transpl, 2005, 11(5): 497-503. DOI: 10.1002/lt.20391.
    [26]
    VIVARELLI M, CUCCHETTI A, LA BARBA G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5): 857-862. DOI: 10.1097/SLA.0b013e3181896278.
    [27]
    JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7): 932-945. DOI: 10.1002/lt.25191.
    [28]
    INVERNIZZI F, IAVARONE M, ZAVAGLIA C, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J]. Transplantation, 2020, 104(3): 568-574. DOI: 10.1097/TP.0000000000002955.
    [29]
    YANIK EL, CHINNAKOTLA S, GUSTAFSON SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634. DOI: 10.1002/lt.24395.
    [30]
    贺强, 周林. 构建以雷帕霉素为主预防肝癌肝移植术后肿瘤复发的综合防治体系[J/CD]. 肝癌电子杂志, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.

    HE Q, ZHOU L. To establish a comprehensive prevention and treatment system based on rapamycin for cancer recurrence after liver transplantation[J/CD]. Electr J Liver Tumor, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.
    [31]
    ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
    [32]
    施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.

    SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepatocellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
    [33]
    SABERIANFAR S, NGUYEN LS, MANOUCHEHRI A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors[J]. Ann Oncol, 2020, 31(4): 543-544. DOI: 10.1016/j.annonc.2020.01.012.
    [34]
    HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463. DOI: 10.1177/1758835919843463.
    [35]
    DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1318) PDF downloads(281) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return